Combined dose-ratio analysis for the CCK-B antagonist virginiamycin in guinea pig ileum.
Corsi
M
M
Glaxo Research Laboratories, Verona, Italy.
Dal Forno
G
G
Oliosi
B
B
Pietra
C
C
van Amsterdam
F T
FT
Trist
D G
DG
D000818:Animals; D001570:Benzodiazepinones / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D010179:Pancreas / Q000378:metabolism; D010671:Phenylurea Compounds; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013758:Tetragastrin / Q000378:metabolism; D014769:Virginiamycin / Q000378:metabolism / Q000494:pharmacology*
D001570:Benzodiazepinones; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D013758:Tetragastrin; D014769:Virginiamycin; C058121:L 365260